

REMARKS

In the present Amendment, claims 5, 14, 17-19, 21 and 24 have been cancelled without prejudice or disclaimer. Claims 6 has been rewritten in independent form, that is, to incorporate the subject matter of claim 5. Claims 20, 25 and 26 have been rewritten in independent form, that is, to incorporate the subject matter of claim 19 excluding formula (1), and to recite that the polymerizable compound is a cationic or anionic polymerizable compound. New claim 28 has been added. Claim 28 corresponds to cancelled claim 24, but depends from claim 20. No new matter has been added, and entry of the Amendment is respectfully requested.

Upon entry of the Amendment, claims 1-4, 6-8, 10, 12, 15, 16, 20 and 25-28 will be pending.

In paragraph No. 4 of the Action, claims 5, 14, 17-19, 21 and 24 are rejected under 35 U.S.C. § 102(b) as allegedly being anticipated by Smothers (U.S. 4,917,977).

Claims 5, 14, 17-19, 21 and 24 have been cancelled, rendering this rejection moot.

In paragraph No. 5 of the Action, claims 19-21 and 24-26 are rejected under 35 U.S.C. § 103(a) as allegedly being unpatentable over Akiba et al (JP 2003-073410).

Applicant submits that this rejection should be withdrawn because Akiba et al does not disclose or render obvious the present invention.

Claims 19, 21 and 24 have been cancelled, leaving only claims 20, 25 and 26 subject to this rejection.

As noted, method claims 20, 25 and 26 have been amended to incorporate the subject matter of claim 19 excluding formula (1), and to recite that the polymerizable compound is a *cationic or anionic polymerizable compound*.

The compounds disclosed in Akiba et al fall within the scope of the compound represented by formula (1). However, formula (1) has been excluded from claims 20, 25 and 26 as amended.

Accordingly, Akiba et al does not teach or suggest the subject matter of claims 20, 25 and 26 as amended.

In view of the above, reconsideration and withdrawal of the § 103(a) rejection of claims 20, 25 and 26 based on Akiba et al are respectfully requested.

Claim 28 is patentable over Akiba et al at least by virtue of its dependency from claim 20.

In paragraph No. 7 of the Action, claims 1-8, 10, 12, 14-21 and 24-27 are *provisionally* rejected for obviousness-type double patenting as allegedly being unpatentable over claims 1-20 of co-pending application 11/510,656 (US 2007/0048666).

In paragraph No. 8 of the Action, claims 1-8, 10, 12, 14-21 and 24-27 are *provisionally* rejected for obviousness-type double patenting as allegedly being unpatentable over claims 1-40 of co-pending application 10/874,344 (US 2005/0003133).

In paragraph No. 9 of the Action, claims 1-8, 10, 12, 14-21 and 24-27 are *provisionally* rejected for obviousness-type double patenting as allegedly being unpatentable over claims 1 and 3-19 of co-pending application 10/925,086 (US 2005/0058910).

In paragraph No. 11 of the Action, claims 1-8, 10, 12, 14-21 and 24-27 are *provisionally* rejected for obviousness-type double patenting as allegedly being unpatentable over claims 1-29 of co-pending application 11/360,439 (US 2006/0194122).

In paragraph No. 12 of the Action, claims 1-8, 10, 12, 14-21 and 24-27 are *provisionally* rejected for obviousness-type double patenting as allegedly being unpatentable over claims 1-21 of co-pending application 11/509,563 (US 2007/0047038).

In paragraph No. 13 of the Action, claims 1-8, 10, 12, 14-21 and 24-27 are *provisionally* rejected for obviousness-type double patenting as allegedly being unpatentable over claims 1-23 of co-pending application 11/359,566 (US 2006/0188790).


In paragraph No. 10 of the Action, claims 1-8, 10, 12, 14-21 and 24-27 are rejected for obviousness-type double patenting as allegedly being unpatentable over claims 1 and 5-18 [sic., claims 1-15] of U.S. Patent No. 7,112,616.

Without admitting that the above seven double patenting rejections are proper, Applicant submits herewith seven Terminal Disclaimers to obviate the rejections.

Allowance is respectfully requested. If any points remain in issue which the Examiner feels may be best resolved through a personal or telephone interview, the Examiner is kindly requested to contact the undersigned at the telephone number listed below.

The USPTO is directed and authorized to charge all required fees, except for the Issue Fee and the Publication Fee, to Deposit Account No. 19-4880. Please also credit any overpayments to said Deposit Account.

Respectfully submitted,



Hui C. Wauters
Registration No. 57,426

SUGHRUE MION, PLLC
Telephone: (202) 293-7060
Facsimile: (202) 293-7860

WASHINGTON DC SUGHRUE/265550

65565

CUSTOMER NUMBER

Date: December 24, 2008